Company intelligence / Profile preview
PharmaBiome
Zurich, Zurich, Switzerlandpharmabiome.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
PharmaBiome is a preclinical-stage company using proprietary microbiome consortia, with initial focus on ulcerative colitis. Its lead platform is validated in preclinical studies, and human clinical entry is projected for 2025[2][4][5][6].
- Therapeutic areas
- OncologyGastroenterology
- Modalities
- Live biotherapeutic product therapyMicrobial therapy
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
03
Partnerships
Ferring PharmaceuticalsRoquette
Beyond the preview
Go deeper on PharmaBiome.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PharmaBiome.